Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
Laura Alder, Dario Trapani, Claire Bradbury, Amanda E.D. Van Swearingen, Sara M. Tolaney, Mustafa Khasraw, Carey K. Anders, Christopher D. Lascola, Liangge Hsu, Nancy U. Lin, Sarah Sammons
Abstract
Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.
Topics & Concepts
MedicineTrastuzumabMetastatic breast cancerOncologyInternal medicineBreast cancerCancerRadiologyBrain Metastases and TreatmentLung Cancer Research StudiesCancer Treatment and Pharmacology